Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0826, ertapenem · 8 trials · 13 indications
| Name | Type | Description |
|---|---|---|
| MK0826, ertapenem sodium / Duration of Treatment: 14 Days | DRUG | - |
| MK0826, ertapenem sodium | DRUG | - |
| Comparator: cefotetan | DRUG | - |
| Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks | DRUG | - |
| MK0826, /Duration of Treatment : 8 Weeks | DRUG | - |
| Comparator: metronidazole / Duration of Treatment: 8 Weeks | DRUG | - |
| Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks | DRUG | - |
| MK0826, ertapenem sodium / Duration of Treatment - 24 weeks | DRUG | - |
| Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks | DRUG | - |
| Comparator: Ticarcillin/Clavulanate | DRUG | - |
| MK0826, ertapenem sodium /Duration of Treatment: 14 Days | DRUG | - |
| Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days | DRUG | - |
Inclusion Criteria: * Male or female patients, 20 years of age or older * Patients did not receive any systemic antibiotic before enrollment, or patients with failed clinical response (no improvement on symptoms or laboratory data) through previous antibiotic treatment * Patients who required thera...
MK0826, ertapenem is an investigational small molecule anti-infective developed by Merck & Company, Inc. (MRK). It has been studied in Phase 3 clinical trials for treating serious bacterial infections, including complicated intra-abdominal infections, sepsis, and infections in colorectal surgery and diabetic foot. It is also known as ertapenem sodium.
MK0826, ertapenem has been studied for the treatment of several bacterial infections: colorectal surgery, complicated intra-abdominal infections, foot infections in diabetic patients, general infection, intra-abdominal infection, and sepsis. These are the indications listed for its clinical development program.
MK0826, ertapenem is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the clinical trials evaluating this anti-infective agent.
MK0826, ertapenem is in Phase 3 clinical development. It is an investigational agent and has not been approved by the FDA for the studied indications. The development program includes both Phase 2 and Phase 3 trials, all of which are completed.
MK0826, ertapenem has been evaluated in completed clinical trials including NCT00481702, a Phase 3 study versus ceftriaxone/metronidazole for intra-abdominal infections; NCT00451386, a Phase 2 pediatric study for urinary tract, skin, and pneumonia infections; NCT00398099, a Phase 3 study in various infections; and NCT00397956, a Phase 3 study in sepsis.
Yes, MK0826, ertapenem is also known as ertapenem sodium. Other alternative names include MK0826, ertapenem sodium /Duration of Treatment: 14 Days, MK0826, ertapenem/Duration of Treatment: 14 Days, MK0826, /Duration of Treatment : 8 Weeks, MK0826,Duration of Treatment: 8 Weeks, MK0826, ertapenem sodium / Duration of Treatment: 14 Days, MK0826, ertapenem/ Duration of Treatment: 14 Days, MK0826, ertapenem sodium / Duration of Treatment - 24 weeks, and MK0826, ertapenem/ Duration of Treatment- 24 weeks.